George Bakris to Adolescent
This is a "connection" page, showing publications George Bakris has written about Adolescent.
Connection Strength
0.727
-
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
Score: 0.095
-
14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S208-S231.
Score: 0.086
-
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
Score: 0.077
-
Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
Score: 0.051
-
Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
Score: 0.040
-
Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73.
Score: 0.037
-
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
Score: 0.035
-
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
Score: 0.033
-
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
Score: 0.033
-
Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343.
Score: 0.028
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
Score: 0.027
-
Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4.
Score: 0.025
-
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
Score: 0.017
-
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
Score: 0.013
-
Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
Score: 0.013
-
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
Score: 0.012
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
Score: 0.010
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
Score: 0.010
-
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
Score: 0.009
-
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
Score: 0.009
-
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
Score: 0.008
-
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
Score: 0.008
-
Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Miner Electrolyte Metab. 1988; 14(6):343-6.
Score: 0.008
-
Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
Score: 0.008
-
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
Score: 0.008
-
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
Score: 0.007
-
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
Score: 0.006
-
The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
Score: 0.006
-
Dermatologic manifestations of lithium: a review. Int J Psychiatry Med. 1980-1981; 10(4):327-31.
Score: 0.005